STAT+: Pharmalittle: We’re reading about an FDA review of Moderna’s flu shot, J&J’s focus on cancer, and more

Johnson & Johnson is prioritizing cancer research and development over the burgeoning obesity drug market, according to Bloomberg News. CEO Joaquin Duato stated the company's ambition to be the leading global cancer company, with oncology as a key growth area. This strategic focus was reinforced by J&J's $3.05 billion cash acquisition of Halda Therapeutics last year, which provided access to a novel oral therapy for prostate cancer. This strategic pivot occurs as J&J continues its corporate restructuring following the spin-off of its Kenvue consumer health division. In other pharmaceutical news, the U.S. Food and Drug Administration (FDA) has approved GSK's oral antibiotic, Utebzi, for treating complicated urinary tract infections. Pharmaphorum reported that this approval offers a new treatment avenue against drug-resistant infections, although Utebzi does not introduce a novel mechanism of action. The article also briefly mentions an FDA review of Moderna's flu shot, though specific details were not provided in the excerpt.